HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021GlobeNewsWire • 11/03/21
HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in OncologyGlobeNewsWire • 10/14/21
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancersGlobeNewsWire • 09/15/21
Pre-clinical data on HOOKIPA's arenaviral immunotherapeutic in melanoma published in Nature CommunicationsGlobeNewsWire • 08/05/21
Hookipa Pharma's Cancer Immunotherapy Shows T-Cell Response, Interim Efficacy in Pretreated HPV16+ Cancer SettingsBenzinga • 06/08/21
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancersGlobeNewsWire • 06/07/21
HOOKIPA Pharma Inc. (HOOK) Soars 7.9%: Is Further Upside Left in the Stock?Zacks Investment Research • 05/19/21
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/12/21
HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent HighlightsGlobeNewsWire • 05/12/21
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancersGlobeNewsWire • 04/10/21
HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/18/21
HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 OutlookGlobeNewsWire • 03/18/21
Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising UpsideSeeking Alpha • 12/31/20
HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters' OptionGlobeNewsWire • 12/11/20
HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Preferred StockGlobeNewsWire • 12/09/20